State Street
CTKB icon

State Street’s Cytek Biosciences CTKB Stock Holding History

State Street’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18M Sell
4,123,748
-23,216
-0.6% -$110K ﹤0.01% 2290
2025
Q4 		$20.9M Buy
4,146,964
+62,596
+2% +$291K ﹤0.01% 2246
2025
Q3 		$14.2M Sell
4,084,368
-89,395
-2% -$336K ﹤0.01% 2424
2025
Q2 		$14.2M Sell
4,173,763
-208,411
-5% -$695K ﹤0.01% 2378
2025
Q1 		$17.6M Sell
4,382,174
-128,204
-3% -$664K ﹤0.01% 2208
2024
Q4 		$29.3M Buy
4,510,378
+342,877
+8% +$2.04M ﹤0.01% 2001
2024
Q3 		$23.1M Buy
4,167,501
+194,369
+5% +$1.1M ﹤0.01% 2124
2024
Q2 		$22.2M Sell
3,973,132
-142,727
-3% -$857K ﹤0.01% 2121
2024
Q1 		$27.6M Buy
4,115,859
+118,090
+3% +$934K ﹤0.01% 2034
2023
Q4 		$36.5M Buy
3,997,769
+220,226
+6% +$1.39M ﹤0.01% 1873
2023
Q3 		$20.9M Buy
3,777,543
+370,108
+11% +$2.97M ﹤0.01% 2156
2023
Q2 		$29.1M Buy
3,407,435
+1,348,163
+65% +$12.1M ﹤0.01% 1999
2023
Q1 		$18.9M Buy
2,059,272
+20,927
+1% +$225K ﹤0.01% 2265
2022
Q4 		$20.8M Buy
2,038,345
+8,092
+0.4% +$109K ﹤0.01% 2218
2022
Q3 		$29.9M Buy
2,030,253
+304,433
+18% +$3.95M ﹤0.01% 1943
2022
Q2 		$18.5M Buy
1,725,820
+405,162
+31% +$4.03M ﹤0.01% 2307
2022
Q1 		$14.2M Buy
1,320,658
+1,048,629
+385% +$14.2M ﹤0.01% 2627
2021
Q4 		$4.44M Buy
272,029
+64,590
+31% +$1.35M ﹤0.01% 3297
2021
Q3 		$4.44M Buy
+207,439
New +$4.88M ﹤0.01% 3303

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street's CTKB Position: Q1 2026 in Review

State Street reduced its Cytek Biosciences (CTKB) stake by 0.56% in Q1 2026, selling an estimated $110K and leaving 4,123,748 shares worth $18M. The position accounts for ﹤0.01% of the portfolio, ranked #2290.

State Street first reported a position in CTKB in Q3 2021 and has held it in 19 quarters since. The position peaked at $36.5M in Q4 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • State Street held 4,123,748 shares of Cytek Biosciences worth $18M as of Q1 2026.
  • State Street sold 23,216 Cytek Biosciences shares in Q1 2026, an estimated $110K.
  • Cytek Biosciences made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2290 holding.
  • State Street first reported a position in Cytek Biosciences in Q3 2021 and has held it in 19 quarters since.
  • State Street's Cytek Biosciences position peaked at $36.5M in Q4 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.